Clinical Study on Gastrodin Injection Combined with Ulinastatin in the Treatment of Aneurysmal Subarachnoid Hemorrhage
Objective:To investigate the clinical efficacy of gastrodin injection combined with ulinastatin in the treatment of aneurysmal subarachnoid hemorrhage(aSAH)and its influence on serum inflammatory factors and vascular endothelial function.Methods:A total of 80 patients diagnosed with aSAH and admitted to a hospital between February 2021 and February 2022 were selected for this study.They were assigned into a control group and an observation group by random number table method,each consisting of 40 cases.Patients underwent microcraniotomy or endovascular embolization within 72 hours of onset,followed by routine postoperative care including hemostasis and infection prevention.The control group received ulinastatin for injection in addition to routine treatment,while the observation group received gastrodin injection on the basis of control group.The serum inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)],vascular endothelial function[calcitonin gene-related peptide(CGRP),endothelin-1(ET-1),vascular endothelial growth factor(VEGF)],nerve function[neuron-specific enolase(NSE),S100 calcium binding protein B(S100B)],clinical efficacy and adverse reactions were compared between the two groups.Results:Following treatment,the serum levels of IL-6,IL-8,and TNF-α decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).Plasma CGRP levels increased in both groups(P<0.05),with the observation group showing higer levels than the control group(P<0.05).ET-1 and VEGF levels decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).NSE and S100B protein levels also decreased in both groups(P<0.05),with the observation group exhibiting lower levels than the control group(P<0.05).The total effective treatment rate in the observation group(92.50%)was higher than that in the control group(75.00%,P<0.05).There was no statistically significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of gastrodin injection and ulinastatin demonstrates significant clinical efficacy in the treatment of aSAH patients.This combination effectively alleviates inflammation,enhances vascular endothelial function,regulates nervous function,and does not elevate the risk of adverse reactions.
ulinastatingastrodin injectionaneurysmal subarachnoid hemorrhageinflammatory reactionvascular endothelial function
万方数据
维普
